MSLN and ovarian carcinoma: Another trial (EVEREST-2) is using a similar approach to investigate A2B694, an autologous logic-gated CAR T-cell therapy, in tumors that express MSLN but have lost HLA-A*02 expression, such as colorectal cancer, NSCLC, pancreatic cancer, ovarian cancer, mesothelioma, and other solid tumors that express MSLN and have lost HLA-A*02 expression (NCT06051695).